Study protocol for a randomized controlled trial: Qiliqiangxin in heart failUre: assESsment of reduction in morTality (QUEST)

• Hoofdauteurs: Wenming Yao (Auteur), Iokfai Cheang (Auteur), Shengen Liao (Auteur), Yanli Zhou (Auteur), Fang Zhou (Auteur), Dongjie Xu (Auteur), Zhenhua Jia (Auteur), Liping Chang (Auteur), Haifeng Zhang (Auteur), Xinli Li (Auteur)
• Formaat: Boek
• Gepubliceerd in: BMC, 2020-02-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Abstract Background Qiliqiangxin (QLQX) capsule is a Traditional Chinese Medicine (TCM) that has been approved in China for the treatment of chronic heart failure (CHF). Our previous study showed with a background of standard HF treatment, QLQX capsules further reduced the levels of NT-proBNP and th...